Progression in characterizing the symptoms and treatments for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent development of coronavirus disease 2019 (COVID-19).
Mitigating the spread of a virus as infectious as SARS-CoV-2 requires having ample and accurate diagnostic tests available. However, in the United States, community transmission began to occur before adequate testing measures could be implemented.
Infections with the 2019 novel coronavirus (2019-nCoV) was of clustering onset and more likely to affect older men with comorbid diseases.
The Centers for Disease Control and Prevention (CDC) and other federal, state, and local departments and agencies are taking aggressive measures to slow transmission in the United States.
The CDC has issued 3 recommendations for mitigating a reduction in tuberculosis testing capability.
The novel Fujifilm SILVAMP TB LAM assay offers superior diagnostic sensitivity while also maintaining specificity, compared with standard assay.
Fibronectin may be a potential marker for hepatitis B surface antigen seroclearance.
Bloodstream infections can be accurately distinguished or excluded within a 4- to 8-hour timeframe using the T2Bacteria Panel.
Recent guidelines set forth by an interdisciplinary panel assembled by the American Thoracic Society sought to demystify primary ciliary dyskinesia and address 4 main diagnostic questions.
Standardized definition, guidance on estimation may facilitate understanding of overdiagnosis.
